A Phase II Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy

NCT07176702 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

45

Enrollment

OTHER

Sponsor class

Conditions

Metastatic PDAC
HER2-positive Status

Interventions

DRUG: HLX22 (Recombinant Humanized Anti-HER2 Monoclonal Antibody Injection) in Combination with Trastuzumab and Chemotherapy

Sponsor

Shanghai Zhongshan Hospital

Collaborators

[object Object]